Carl Zeiss Meditec AG Financial Results H1 2021/22 | Performance Insights with CEO and CFO

Carl Zeiss Meditec AG H1 2021/22: Key Takeaways Carl Zeiss Meditec AG Demonstrates Growth Amidst Global Challenges In an insightful video presentation, Carl Zeiss Meditec AG, a leading figure in the medical technology sector, has once again proven its resilience and capacity for growth amidst ongoing global challenges. The first half of the fiscal year 2021/22 has seen the company achieve a notable revenue increase to €855.4 million, up from €767.4 million in the previous year, marking an 11.5% growth (10.7% when adjusted for currency effects). This achievement is particularly commendable given the backdrop of a strained supply chain due to the war in Ukraine and COVID-19 lockdowns in China, as CEO Dr. Markus Weber highlighted. The presentation, led by the CEO and CFO, delves into the specifics of this growth, attributing it to significant contributions from all strategic business units and regions. Noteworthy is the Ophthalmic Devices segment, which saw a 10.5% revenue increase, and the Microsurgery segment, which experienced a 14.8% growth. With China and India leading the charge, the APAC region posted a 17.1% revenue increase, underscoring the company’s strong market presence in these countries. Despite the positive revenue growth and a slight increase in EBIT to €177.3 million, the company noted a slight dip in the EBIT margin to 20.7%, mainly due to planned higher investments in Sales & Marketing and R&D. Nevertheless, earnings per share rose to €1.44 from the previous year’s €1.12. Amidst these achievements, the company remains cautiously optimistic about the future, citing ongoing global supply chain strains and political uncertainties as potential hurdles. However, Carl Zeiss Meditec AG stands firm in its forecast for the fiscal year, anticipating revenue growth to match or surpass market trends, with an expected EBIT margin ranging between 19-21%. This comprehensive overview showcases Carl Zeiss Meditec AG’s robust half-year performance and highlights its strategic approach to overcoming global market challenges. It offers valuable insights to professional stock investors regarding the company’s resilience and growth prospects. Key Contributors to GrowthFinancial Highlights and Future Outlook ▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.